WINSTON-SALEM, N.C., May 2, 2019 /PRNewswire-PRWeb/ -- Precise Bio, a Regenerative Medicine company that is advancing
"Since establishing our dedicated ophthalmology business unit in October 2018, we have made significant progress in expanding our pipeline in multiple ophthalmic indications," said Mr. Batt. "We are leveraging our ability to manufacture ocular tissues and work with ocular cells into preclinical studies in several indications, including conditions that have significant unmet medical need. We hope to be able to share promising results from some of these programs in the coming months. We are pleased to have the opportunity to share our progress with our colleagues at OIS."
Innovating New Treatments for LSCD-Related Conditions In 2018 Precise Bio was the first company to transplant a 3D-printed cornea graft in animals. In 2019, the company initiated preclinical studies to evaluate a bio-fabricated ocular surface transplant (OST) for the treatment of limbal stem cell deficiency (LSCD), a devastating condition that results in corneal blindness.
Precise Bio's OST is an allogeneic engineered tissue comprising limbal stem cells and other biomaterials designed for a simple procedure that can be performed in a physician's office. The OST program leverages the proven technologies that Precise Bio developed for its cornea transplant program.
An Unparalleled Integrated 4D Bio-Fabrication Platform Enables Innovation Precise Bio's proprietary, laser-based 3D bio-printing technology, together with a complete 4D bio-fabrication platform, enables scale-up of traditional tissue engineering methods, making tissues and organs available for clinical use. The technology will allow cost-effective, reproducible and large-scale production of tissues and organs that meet stringent quality control criteria. The company's innovative 4D-bio-fabrication technology is a true platform for innovation and includes cell expansion, bio-materials, processes, 3D bio-printing and other required critical technologies. Key advantages of this platform compared with other bio-fabrication approaches are that it is able to generate complex tissues in a highly reproducible manner and to apply lessons learned from the fabrication of one tissue to the next. This allows for rapid innovation and product development, and provides a foundation on which to build a robust pipeline of proprietary products with substantial clinical and commercial value. This platform can solve critical limitations of existing 4D bio-fabrication technologies and is paving the way for the engineering of more complex tissues and organs.
Precise Bio is currently in discussions with pharmaceutical companies to explore opportunities to leverage its technologies and expertise to print ocular tissues and design an "eye on a chip" to facilitate development of novel drugs for ophthalmic indications.
"Precise Bio's 4D bio-fabrication production process opens the door to developing a broad array of novel therapies for treating ophthalmic indications that are not effectively addressed today," said Shay Soker, PhD, Professor at the Wake Forest Institute of Regenerative Medicine (WFIRM) and a co-founder of Precise Bio. "Ophthalmic tissues are complex, comprising multiple cell types and layers. Precise Bio's technology is the only one that accurately recapitulates the natural complexity needed for normal ophthalmic function. Our technology has the potential to revolutionize the treatment of multiple ophthalmic diseases."
OIS Presentation Information
Session title: Innovation Showcase I Presentation title: Bio-Fabricated Tissues and Organs for Ophthalmology Presenter: Aryeh Batt, co-founder and CEO of Precise Bio Presentation time: May 2, 2019, 9:58 a.m. PDT Presentation location: Hilton San Diego Bayfront
About OIS The Ophthalmology Innovation Summits facilitate meaningful interactions and the exchange of information between clinical, capital and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs. The OIS even held in conjunction with the ASCRS Annual Meeting unites over 500 industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs.
About Precise Bio Precise Bio is a regenerative medicine company developing and commercializing break-through, proprietary regenerative medicine technologies and cellular therapies that can transform patient care across a wide range of medical indications. The company's proprietary 3D bio-printing platform overcomes limitations of existing extrusion and Ink-jet printers and paves the way for printing of clinically viable tissues and organs.
The company was founded by Dr. Anthony Atala, director of the Wake Forest Institute of Regenerative Medicine (WFIRM), Prof. Shay Soker from WFIRM and Mr. Aryeh Batt, who developed the company's transformative and proprietary laser printing technology, and serves as the company's CEO. The company has established collaborations with world-class partners who bring demonstrated expertise in complementary technologies that can be leveraged on Precise Bio's platform in order to reproducibly manufacture functional tissues.
Corporate Contact Precise Bio Aryeh Batt, CEO 336-671-5571 Aryeh.batt(at)precise-bio.com
Media Contact Lazar Partners Erich Sandoval 917-497-2867 esandoval(at)lazarpartners.com
SOURCE Precise Bio
Subscribe to our Free Newsletters!